MyMD Pharmaceuticals (NASDAQ:MYMD) is a clinical-stage biotechnology company focused on the development of targeted immunotherapies for oncology and immuno-metabolic disorders. The company’s proprietary platform leverages engineered cytokine receptors to selectively deliver therapeutic payloads to diseased tissues, with an emphasis on improving efficacy while minimizing systemic toxicity. MyMD’s lead candidate, MDNA55, is designed to target the interleukin-4 receptor (IL-4R) and has been evaluated in recurrent glioblastoma patients. Additional pipeline assets include MDNA19, aimed at chronic inflammatory diseases, and MDNA11, an engineered interleukin-2 variant for solid tumors, as well as MDNA109 for metabolic disorders.
MDNA55 represents a novel fusion of a modified IL-4 ligand with a cytotoxic payload derived from Pseudomonas exotoxin, enabling direct cell death in IL-4R–overexpressing tumors. This therapeutic approach has advanced through multiple clinical studies, demonstrating a unique mechanism of action compared with conventional chemotherapies and emerging immuno-oncology agents. MDNA19 and MDNA11 are both rooted in MyMD’s cytokine receptor toolbox, which seeks to harness or modulate key immune pathways implicated in autoimmune diseases and cancer, respectively. Preclinical data for these candidates highlight favorable pharmacokinetic profiles and targeted activity in relevant disease models.
Founded in 2018, MyMD Pharmaceuticals went public in 2020 and is headquartered in Greenwich, Connecticut. The company collaborates with academic research centers and contract research organizations across North America and Europe to advance its clinical programs. These partnerships underpin MyMD’s strategy to maximize development efficiency, while ensuring access to cutting-edge research and patient populations.
MyMD’s leadership team is led by President and Chief Executive Officer Dr. David Giljohann, whose prior experience includes senior roles in drug discovery and development at both biotech firms and major pharmaceutical companies. The board of directors and scientific advisory board comprise industry veterans with deep expertise in oncology, immunology, and translational research. Together, they guide the company’s efforts to deliver differentiated therapies that address high-unmet-need indications.
